

**OPTN/UNOS Histocompatibility Committee
Meeting Minutes
October 30, 2017
Conference Call**

**Robert Bray, PhD, D(ABHI), Chair
Cathi Murphey, PhD, HCLD/CC(ABB), Vice Chair**

Introduction

The Histocompatibility Committee (the Committee) met via Citrix GoToTraining teleconference to discuss the following agenda items:

1. Vote on Review of HLA Tables (2016) Proposal

The following is a summary of the Committee’s discussions.

1. Vote on Review of HLA Tables (2016) Proposal

The Review of HLA Tables (2016) proposal was out for public comment from July 31, 2017 – October 2, 2017. The Committee made final post public comment changes at the in person meeting on October 24, 2017, and agreed to schedule a voting meeting to answer any outstanding questions and take a final vote.

Summary of discussion:

At the in person meeting on October 24, 2017, the Committee brought up the idea of removing a number of broad antigens from the equivalency tables that have split antigens (HLA-A9, 10, 19, 28; HLA-B 5, 12, 14, 15, 16, 17, 21, 22; HLA-C3; HLA-DR51, 52, 53; and HLA-DQ1). The Committee requested frequencies for these broad antigens currently in UNetSM in order to gauge the impact of removing them from the system. UNOS Research Staff produced a report with these frequencies which was presented on the teleconference.

Figure 1: Frequencies of Broad Antigens in UNet

Locus	Antigen	Donor HLA (2016-7/2017)	WL registrations (10/20/2017)	KI, KP, PA WL registrations (10/20/2017)	WL UAs (10/20/2017)
A	9	0	3	1	1195
A	10	3	36	35	615
A	19	0	2	1	260
A	28	0	163	159	1285
B	5	0	9	9	848
B	12	0	6	6	1160
B	15	3	87	82	554
B	16	0	5	4	530
B	17	0	7	7	1509
B	21	1	2	2	836
B	22	0	4	3	720
C	3	61	882	864	645
DR	2	0	29	28	603
DR	3	3	236	219	650
DR	5	0	5	4	473
DR	6	0	18	17	504
DQ	1	0	645	637	593
			2,139	2,078	5,024

Some Committee members were surprised by the number of registrations on the waiting list that contained broad antigens. Given the short amount of time available to produce the report, UNOS Research Staff was unable to provide numbers on how many of the candidates with a broad antigen listed also had the split antigen listed. After considering the number of candidates and donors that would possibly be impacted by removing these broad antigens, along with some of the possible effects on CPRA values, the Committee agreed not to remove these broad antigens at this time and to instead further investigate the effects of removing them in the next equivalency table update. The Committee was also interested in learning more about lab specific antigen listing practices and may provide some education in the future.

The Committee voted unanimously (14 yes; 0 no; 0 abstain) to approve the policy language and send the proposal to the Board of Directors for consideration at the December 2017 meeting.

Next steps:

The proposal will be voted on at the December 4-5, 2017, Board of Directors meeting.

Upcoming Meeting

- November 14, 2017

Attendance

- **(Sub)Committee Members**
 - Robert Bray
 - Cathi Murphey
 - Laurine Bow
 - Cathy Gebhardt
 - Steven Geier
 - Chantale Lacelle
 - Peter Lalli
 - Mayra Lopez-Cepero
 - John Lunz
 - Gabriel Maine
 - Rajalingam Raja
 - Carley Shaut
 - Craig Van De Walker
 - Melissa Yeung

- **OPTN/UNOS Staff**
 - Alison Wilhelm
 - James Alcorn
 - Jason Chicirda
 - Emily Kneipp
 - Anna Kucheryavaya
 - Kimberly Taylor